By Dr. Priya Nair, Health Technology Reviewer
Last updated: May 14, 2026

SELECT Trial Reveals GLP-1 Medications Could Enhance Longevity Beyond Weight Loss

In a remarkable finding from the SELECT trial, GLP-1 medications such as semaglutide have demonstrated a potential to recalibrate our understanding of longevity beyond mere weight loss. The trial discovered a striking 20% reduction in cardiovascular events among participants using these medications, challenging the prevailing narrative that positions GLP-1s solely as tools for managing obesity. This insightful data not only highlights the medications’ capabilities but also sets the stage for broader discussions on chronic disease prevention and aging biology.

While many discussions around GLP-1 treatments have thus far fixated on their weight loss properties, the SELECT trial’s results indicate that they may also influence biological pathways associated with aging. The implications for public health, particularly given the current obesity epidemic and the staggering number of Americans living with diabetes—over 34 million—are profound. Investors, healthcare strategists, and wellness advocates should take note.

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) medications are a class of drugs primarily prescribed to treat type 2 diabetes and assist in weight management. By mimicking the effects of the GLP-1 hormone, they enhance insulin secretion, inhibit glucagon release, and promote satiety, which helps regulate blood sugar levels. Think of them as a muscle car engine—while they may primarily be known for their speed (or weight-loss benefits), there’s much more under the hood, including an evolving symphony of health benefits waiting to be explored, as noted in the 5 Ways Health Performance Dashboards Are Revolutionizing Patient Care.

As obesity and diabetes increasingly become public health concerns, understanding the broader implications of these medications is crucial. The SELECT trial adds layers to our comprehension of GLP-1s, presenting compelling evidence that their impact could extend into the realms of longevity and overall health.

How GLP-1 Works in Practice

The SELECT trial’s findings underscore more than just the weight loss capabilities of semaglutide, revealing its multifaceted potential across various settings.

1. Novo Nordisk and Cardiovascular Benefits: The SELECT trial, conducted by Novo Nordisk, involved over 17,000 participants and examined semaglutide’s impact on cardiovascular health in individuals with obesity and type 2 diabetes. The trial reported a notable 20% reduction in cardiovascular events among users of GLP-1 medications, indicating significant health benefits beyond weight management alone.

2. Eli Lilly’s Investigative Approach: Eli Lilly, a major competitor in the diabetes medication market, is exploring the potential longevity applications of its own GLP-1 medication, tirzepatide. Preliminary studies suggest that tirzepatide may also contribute to cardiovascular health, further igniting interest in the potential of GLP-1 drugs to affect age-related biological processes, as discussed in How Calico’s $1 Billion Bet Could Revolutionize Longevity Science.

3. Research Insights on Neuroinflammation: Recent studies are examining how GLP-1 receptor activation can mitigate neuroinflammation, a key factor in both cognitive decline and neurodegenerative diseases. Activating this pathway may initiate positive changes in cognitive health, suggesting that GLP-1 medications could play a role in combating conditions like Alzheimer’s, underscoring the need for more extensive research on their impact on aging processes.

The SELECT trial’s findings reveal a broader purpose for GLP-1 medications, signaling a need for more comprehensive studies to understand how these drugs can mitigate age-related decline.

Top Tools and Solutions

When navigating the rapidly evolving field of GLP-1 medications and their potential impact on longevity, certain tools can enhance your understanding and strategic planning.

1. Trainual — A business playbook and employee training platform that can help health professionals and organizations efficiently disseminate knowledge about health trends and medication uses.

2. InboxAlly — An email deliverability improvement tool great for health-focused organizations looking to communicate effectively about new strategies related to diabetes and GLP-1 treatments.

3. Kartra — An all-in-one online business platform that can facilitate marketing efforts related to pharmaceutical advancements, including GLP-1 medication education.

4. Amplemarket — AI sales automation tools that can help health organizations target their messaging about innovative health solutions effectively.

In conclusion, the SELECT trial’s findings about GLP-1 medications emphasize their potential that transcends weight loss. As further research unfolds, healthcare stakeholders must stay abreast of developments to harness the full capabilities of these treatments in enhancing longevity and overall health outcomes.